On January 27, 2020, INmune Bio, Inc. (the "Company") reported that it has entered into an agreement (the "Repurchase Agreement") to purchase 220,000 shares of its common stock, par value $0.001 per share (the "Shares") from Linda F. Powers. The purchase price is $4.60 per share, resulting in a total purchase price of $1,012,000 (the "Repurchase Transaction") which the company believes is an attractive price and will be accretive (Filing, 8-K, INmune Bio, JAN 27, 2020, View Source [SID1234553569]). Prior to consummating the Repurchase Transaction, Ms. Powers held approximately 10.4% of the Company’s outstanding common stock. Following the consummation of the Repurchase Transaction, Ms. Powers now holds approximately 8.6% of the Company’s outstanding common stock. The Repurchase Agreement and the transactions contemplated therein, were approved by the Company’s board of directors and audit committee.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The foregoing is merely a brief description of the material terms of the Repurchase Agreement, which is attached hereto as Exhibit 10.1 and incorporated herein by reference. The foregoing does not purport to be a complete description of the rights and obligations of the parties thereunder and such description is qualified in its entirety by reference to such exhibit.